ライフサイエンスコーパス: palmar

1 s, at least for a time, for the treatment of palmar and axillary hyperhidrosis.

2 The palmar and dorsal ulnotriquetral and ulnolunate ligament

3 Immunostaining of Cx26 in lesional palmar and knuckle skin was weak or absent, although its

4 c signaling pathways in fibroblasts from the palmar and nonpalmar dermis of Dupuytren's patients and

5 3000), which each entail painful calluses on palmar and plantar skin.

6 ling arthritic changes, marked osteoporosis, palmar and plantar subcutaneous nodules and distinctive

7 alignant melanoma typically occurring on the palmar and plantar surfaces.

8 rome include multiple basal cell carcinomas, palmar and/or plantar pits, odontogenic keratocysts, ske

9 iated with incompleteness of the superficial palmar arch ( P=0.13).

10 Incompleteness of the superficial palmar arch (SPA) was present in 46%, the deep palmar ar

11 measure the pressure-derived function of the palmar arch and forearm arterial collateral circulation

12 irect invasive hemodynamic assessment of the palmar arch and forearm arterial function reveals collat

13 Palmar arch and forearm collateral function was determin

14 Before invasive CFI measurements, arterial palmar arch and forearm function was tested noninvasivel

15 The rate of palmar arch incompleteness and the clinical consequences

16 lmar arch (SPA) was present in 46%, the deep palmar arch was complete in all patients.

17 upply is always preserved by a complete deep palmar arch.

18 The palmar arches serve as the most important conduits for d

19 romoted differentiation into specifically of palmar dermal fibroblasts from Dupuytren's patients in t

20 ith the peak systolic velocity of the second palmar digital artery (Pearson coefficient: 0.621; p < 0

21 CR) analysis and immunohistochemistry of the palmar epidermis demonstrated significantly increased ex

22 ratum granulosum of both normal and affected palmar epidermis, indicating that the altered AQP5 prote

23 Human palmar fascia fibroblasts and human fetal lung fibroblas

24 ive fibroproliferative disease affecting the palmar fascia of the hands, causing fingers to irreversi

25 disabling fibroproliferative disorder of the palmar fascia, which leads to flexion contractures of th

26 nonpalmar dermis of Dupuytren's patients and palmar fibroblasts from non-Dupuytren's patients.

27 Palmar finger skin reacts to extension under mechanical

28 Facial, axillary, and/or palmar hyperhidrosis (excessive sweating of the face, ar

29 altered thumb print due to other causes and palmar hyperhidrosis were excluded.

30 A prospective randomized study on palmar hyperhidrosis, May 2016-September 2019.

31 bioenergetics in 13 patients with idiopathic palmar hyperhidrosis.

32 cise performance in patients with idiopathic palmar hyperhidrosis.

33 mediate phenotype most readily identified by palmar hyperlinearity and in some cases fine-scale and/o

34 mon skin disorder characterised by dry skin, palmar hyperlinearity and keratosis pilaris.

35 Trained observers were able to define palmar hyperlinearity in the majority (3191/3656, 87%) o

36 Palmar hyperlinearity is a feature of ichthyosis vulgari

37 s of IV are fine-scale on the arms and legs, palmar hyperlinearity, and keratosis pilaris.

38 ong adduction of the thenar, hypothenar, and palmar interosseous muscles offer powerful rigidity to t

39 il thickening in PC-K6a and PC-K17; (3) more palmar keratoderma in PC-K16; (4) cysts primarily in PC-

40 Our findings show that palmar keratoderma is a clinical indicator of recessive

41 pe of EPP which is characterized by seasonal palmar keratoderma, relatively low erythrocyte protoporp

42 ited Kingdom identified six individuals with palmar keratoderma.

43 he new species exhibits the oldest record of palmar (or true) opposition of the pollex, which is unpr

44 at can progress to parasagittal fractures or palmar osteochondral disease (POD).

45 The digit and palmar pads are also represented by barrelettes located

46 Dose-limiting toxicities were grade 3 palmar plantar erythrodysesthesia (PPE), mucositis, and

47 nt but required early dose reductions due to palmar plantar erythrodysesthesia, and liver decompensat

48 stinal toxicity, hypothyroidism, fatigue and palmar plantar erythrodysesthesia.

49 a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin.

50 ns affecting nails, glands, oral mucosa, and palmar-plantar epidermis.

51 worse treatment-related adverse events were palmar-plantar erythrodysaesthesia (1 [<1%] of 367 patie

52 ing placebo, the most frequent of which were palmar-plantar erythrodysaesthesia (13 [10%] vs 0), hype

53 , fatigue (24 [8%]), dyspnoea (21 [7%]), and palmar-plantar erythrodysaesthesia (18 [6%]) in the sora

54 vs 39 [12%] of 320 in the sunitinib group), palmar-plantar erythrodysaesthesia (25 [8%] vs 26 [8%]),

55 ase (37 [9%] vs eight [4%] vs 18 [10%]), and palmar-plantar erythrodysaesthesia (35 [8%] vs 17 [8%] v

56 n (90 [17%] of 535), fatigue (51 [10%]), and palmar-plantar erythrodysaesthesia (49 [9%]).

57 n with sorafenib than with axitinib included palmar-plantar erythrodysaesthesia (PPE; 37 [39%] of 96

58 %]), diarrhoea (109 [27%] vs 105 [54%]), and palmar-plantar erythrodysaesthesia (seven [2%] vs 100 [5

59 d to erdafitinib were stomatitis (25 [12%]), palmar-plantar erythrodysaesthesia syndrome (12 [6%]), a

60 ] vs 7 [2%]), fatigue (36 [11%] vs 24 [7%]), palmar-plantar erythrodysaesthesia syndrome (27 [8%] vs

61 5%] of 269 patients in the sorafenib group), palmar-plantar erythrodysaesthesia syndrome (33 [12%] vs

62 5%] of 269 patients in the sorafenib group), palmar-plantar erythrodysaesthesia syndrome (33 [12%] vs

63 hoea (103 [21%] of 488 patients) followed by palmar-plantar erythrodysaesthesia syndrome (87 [18%]),

64 fatigue in the axitinib arm, and diarrhoea, palmar-plantar erythrodysaesthesia, and alopecia in the

65 PLD-treated patients experienced more palmar-plantar erythrodysesthesia (37%; 18% grade 3, 1 p

66 atigue (6% v 15%), hypertension (28% v 22%), palmar-plantar erythrodysesthesia (8% v 4%), and hematol

67 a (n = 69 [48.6%]), nausea (n = 65 [45.8%]), palmar-plantar erythrodysesthesia (n = 62 [43.7%]), cons

68 Palmar-plantar erythrodysesthesia (PPE) became evident a

69 cause of adverse events related to the drug (palmar-plantar erythrodysesthesia [PPE], n = 3; asthenia

70 ful neuropathy occurred in 7.5%; and grade 3 palmar-plantar erythrodysesthesia occurred in 2.5%.

71 worse treatment-related adverse events were palmar-plantar erythrodysesthesia syndrome (18 [10%] in

72 The most common adverse events were palmar-plantar erythrodysesthesia syndrome (38.1%), alop

73 fatigue, hypertension, febrile neutropenia, palmar-plantar erythrodysesthesia syndrome, and stomatit

74 ts in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fati

75 ncidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapat

76 events were fatigue, weight loss, diarrhea, palmar-plantar erythrodysesthesia, and hypertension.

77 mg twice per day; n = 1); grade 3 mucositis, palmar-plantar erythrodysesthesia, and hypokalemia (400

78 Skin rash, palmar-plantar erythrodysesthesia, and thrombocytopenia

79 of whom had three dose-limiting toxicities: palmar-plantar erythrodysesthesia, cerebral ischaemia, a

80 associated adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased weight and

81 5% of patients) were diarrhea, nausea, rash, palmar-plantar erythrodysesthesia, mucositis, vomiting,

82 as 1,657 mg/m2/d with limiting toxicities of palmar-plantar erythrodysesthesia, nausea, vomiting, ver

83 ction, elevated thyroid stimulating hormone, palmar-plantar erythrodysesthesia, weight loss, and head

84 grade 3 events were skin toxicity (rash and palmar-plantar erythrodysesthesia; five [4%]) and hypert

85 Painful palmar-plantar keratoderma (PPK) severely impairs mobili

86 on in a family with diffuse nonepidermolytic palmar-plantar keratoderma was shown to be the loss in o

87 Ewing sarcoma, three [7%] for osteosarcoma), palmar-plantar syndrome (three [7%] for Ewing sarcoma, t

88 cognized, but important, normal functions in palmar-plantar tissues.

89 The remarkable occurrence of severe palmar--plantar hyperkeratosis in both patients suggests

90 ressed in ectoderm-derived appendages and in palmar/plantar epidermis and is robustly induced when th

91 d protein electrophoretic features closer to palmar/plantar or mucosal-like epithelia.

92 erse metacarpal ligament (DTML) (n = 5), and palmar plate (n = 10) were analyzed.

93 ittal MR images were best for evaluating the palmar plate and the capsule.

94 n of lesions of the extensor hood, DTML, and palmar plate structures.

95 many medical conditions such as plantar and palmar psoriasis, dyshidrosis, and cholestasis.

96 , radioscapholunate, dorsal radiotriquetral, palmar scaphotriquetral, and dorsal scaphotriquetral lig

97 Results were compared to tape strips from palmar skin of age/race/sex-matched healthy controls (HC

98 By simulating skin deformations across the palmar surface of the hand and tiling it with receptors

99 Injection of capsaicin into the plantar or palmar surface of the paws produced a depression of brad

100 We examined the palmar surfaces of the dominant and nondominant hands of

101 gueta (GUA), Roseira (ROS), Santa Vitoria do Palmar (SVP), and Taubate (TBT).

102 Despite limited sensation, palmar tactile stimulation delivered 4 months post-trans

103 The capitate head is more palmar than in all other known hominoids, permitting ext

104 rgone AHSCT, namely finger pad inflammation, palmar violaceous papules, and digital ulcerations.

105 rgone AHSCT, namely finger pad inflammation, palmar violaceous papules, and digital ulcerations.